This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Stocks in Motion

Shares of Epix Pharmaceuticals (EPIX) were among the best-performing health-related stocks Friday, rising 20.8% after the company said the Food and Drug Administration accepted its response to an approvable letter the company received in January.

The FDA will now review the company's new drug application for Vasovist -- as well Epix's May response to the approvable letter. The FDA expects to issue an action letter on the imaging agent in late November, Epix said. "Although we are not yet in agreement with the FDA, we look forward to discussing the scientific issues with them as they review our complete response," the company said. Epix also said that during the review process "the FDA could again request additional studies or other information before granting approval for Vasovist." Shares traded up $1.84 to $10.69.

Coventry Health Care (CVH) fell modestly after the company said that it completed the financing of $450 million in new credit facilities and remains comfortable with second-quarter earnings guidance. The new facilities consist of a five-year, $350 million revolver and a five-year, $100 million term loan. In connection with the payoff and elimination of its previous credit facilities, the company expects to take a noncash charge totaling $5.4 million during the second quarter.

In unrelated transactions, the company will record a $2.6 million gain on the sale of investments in the second quarter. In all, the transactions are expected to cut 2 cents from its fully diluted earnings. The company said that, notwithstanding the one-time items, it still remains comfortable with its second-quarter earnings guidance.

Shares of iCAD (ICAD - Get Report) fell 23.3% after the company said it expects to post a year-over-year decline in second-quarter sales. The medical technology company said that when it reports second-quarter results on July 28, it would post sales of about $4.5 million. A year ago, the company reported sales of $5.64 million. The company said the decline in sales is due to a customer shift into the company's lower-cost products. Shares traded down $1.04 to $3.43.

Amedisys (AMED - Get Report) rose 2.5% after the company agreed to acquire privately held Housecall Medical Resources for $106 million. The acquisition will be funded by a combination of cash on hand and senior secured credit facilities that Amedisys secured from Wachovia Bank and GE Healthcare Financial Services. The acquisition, which is expected to close by the end of July, will add 5 cents to 10 cents a share in earnings during 2005 and add 25 cents to 30 cents a share in 2006. Housecall Medical, which operates 57 home health agencies and nine hospice locations, posted sales of about $103 million over the past 12 months. Shares of Amedisys traded up 92 cents to $37.70.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
EPIX $5.95 0.00%
AMED $40.43 0.00%
ICAD $3.92 0.00%
JNJ $92.64 -0.76%
MRK $52.65 -0.62%

Markets

Chart of I:DJI
DOW 16,374.76 +23.38 0.14%
S&P 500 1,951.13 +2.27 0.12%
NASDAQ 4,733.4970 -16.4820 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs